ABSTRACT
Between March 85 and November 86, 20 patients underwent treatment for sudden deafness [19] or bilateral tinnitus [1] by Pentoxifylline (1 200 mg/24 Hrs, including 400 mg IV over 24 Hrs) and Carbogen sessions (2 or 3/24 Hrs), during six days on an in-patient basis, followed by 1 200 mg/24 Hrs orally during another eight days. The results, assessed by clinical examination, audiometry, and erythrocyte filtration time (using the Reid and Dormandy method) on the first, sixth, and fourtheenth days, were: -- good or very good a little more than 75%, -- moderate: 5%, -- poor: a little fewer than 20%. Filtration times in a group of asymptomatic patients, determined by the same method, were used as a reference.
Subject(s)
Erythrocyte Deformability , Hearing Loss, Sudden/drug therapy , Pentoxifylline/therapeutic use , Theobromine/analogs & derivatives , Adolescent , Adult , Aged , Audiometry , Blood Viscosity/drug effects , Erythrocyte Deformability/drug effects , Female , Hearing Loss, Sudden/etiology , Humans , Male , Middle Aged , Pentoxifylline/pharmacology , PrognosisABSTRACT
The authors report the case of a 62 years old patient who presented a squamous laryngeal carcinoma 8 years after the discovery of amyloidosis localized to one vocal cord. In this patient, a relationship would seem to exist between the two pathologies, with degeneration of amyloidosis being responsible, though a random coexistence cannot, of course, be completely excluded. After a review of laryngeal amyloidosis and its management, this particular case is discussed in relation to other cases described in the literature.
Subject(s)
Amyloidosis/complications , Carcinoma, Squamous Cell/etiology , Laryngeal Neoplasms/etiology , Vocal Cords , Humans , Laryngeal Diseases/complications , Laryngeal Diseases/pathology , Laryngectomy , Male , PrognosisABSTRACT
The authors list the main modalities for medical therapy proposed for sero-mucous otitis. Treatments such as antibiotherapy, corticotherapy and antihistamines have not proved to be effective, although they are useful at certain stages of the disease. The authors present a study of a mucolytic, carbocysteine, for the treatment of sero-mucous otitis. The study was performed using a double blind procedure against placebo in 44 children aged from 30 months to ten years. Monitoring included a clinical examination, impedancemetry, and audiometry. With carbocysteine, the auditive recovery was significantly faster on the side of the least affected ear. When transtympanic drainage had to be performed, the mucolytic effect in vivo on the fluidity of the secretions was directly noted. An improved ear evacuation was obtained. Tolerance was perfect in prolonged treatment with a high posology in young children.
